Bronchopulmonary Dysplasia and the Oxidative Puzzle: Current and New Strategies for Neonatal Health.

IF 6.8 2区 生物学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY
Jiaying Liu, Riyan Huang, Li Fu, Zhenzhuang Zou, Bo Huang
{"title":"Bronchopulmonary Dysplasia and the Oxidative Puzzle: Current and New Strategies for Neonatal Health.","authors":"Jiaying Liu, Riyan Huang, Li Fu, Zhenzhuang Zou, Bo Huang","doi":"10.1177/15230864261486341","DOIUrl":null,"url":null,"abstract":"<p><p><i>Significance:</i> Bronchopulmonary dysplasia (BPD) remains a major chronic lung disease of prematurity and an important cause of long-term respiratory morbidity in preterm infants. As survival of extremely preterm infants has improved, the clinical burden of BPD has remained substantial. Redox dysregulation, characterized by an imbalance among oxidant exposure, antioxidant capacity, and adaptive signaling responses, represents a central pathogenic mechanism in BPD and contributes to impaired alveolar and vascular development, inflammatory amplification, and defective lung repair.<i>Recent Advances:</i> Current neonatal management strategies, including optimized respiratory support, careful oxygen targeting, nutritional support, caffeine therapy, and selective corticosteroid use, may reduce oxidant burden or modulate redox-sensitive injury pathways. In parallel, antioxidant-related interventions-including vitamins, trace elements, glutathione-related therapies, natural products, and pharmacological agents-have demonstrated biological plausibility.<i>Critical Issues:</i> Current interventions do not consistently correct the underlying redox imbalance of the immature lung. The clinical translation of antioxidant-related therapies remains limited and highly dependent on the level of evidence, intervention timing, and biological context. This review summarizes the role of redox dysregulation in the pathogenesis of BPD and critically examines the clinical and preclinical evidence for redox-related interventions.<i>Future Directions:</i> Emerging priorities include biomarker-guided therapy, omics-informed risk stratification, targeted pulmonary delivery, precision nutritional strategies, and integrated multimodal approaches. Future progress in BPD prevention and treatment will likely depend on integrating redox-informed approaches with established neonatal care, targeted interventions, and rigorous long-term clinical evaluation. <i>Antioxid. Redox Signal.</i> 00, 000-000.</p>","PeriodicalId":8011,"journal":{"name":"Antioxidants & redox signaling","volume":" ","pages":"15230864261486341"},"PeriodicalIF":6.8000,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antioxidants & redox signaling","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1177/15230864261486341","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Significance: Bronchopulmonary dysplasia (BPD) remains a major chronic lung disease of prematurity and an important cause of long-term respiratory morbidity in preterm infants. As survival of extremely preterm infants has improved, the clinical burden of BPD has remained substantial. Redox dysregulation, characterized by an imbalance among oxidant exposure, antioxidant capacity, and adaptive signaling responses, represents a central pathogenic mechanism in BPD and contributes to impaired alveolar and vascular development, inflammatory amplification, and defective lung repair.Recent Advances: Current neonatal management strategies, including optimized respiratory support, careful oxygen targeting, nutritional support, caffeine therapy, and selective corticosteroid use, may reduce oxidant burden or modulate redox-sensitive injury pathways. In parallel, antioxidant-related interventions-including vitamins, trace elements, glutathione-related therapies, natural products, and pharmacological agents-have demonstrated biological plausibility.Critical Issues: Current interventions do not consistently correct the underlying redox imbalance of the immature lung. The clinical translation of antioxidant-related therapies remains limited and highly dependent on the level of evidence, intervention timing, and biological context. This review summarizes the role of redox dysregulation in the pathogenesis of BPD and critically examines the clinical and preclinical evidence for redox-related interventions.Future Directions: Emerging priorities include biomarker-guided therapy, omics-informed risk stratification, targeted pulmonary delivery, precision nutritional strategies, and integrated multimodal approaches. Future progress in BPD prevention and treatment will likely depend on integrating redox-informed approaches with established neonatal care, targeted interventions, and rigorous long-term clinical evaluation. Antioxid. Redox Signal. 00, 000-000.

支气管肺发育不良和氧化之谜:当前和新生儿健康的新策略。
意义:支气管肺发育不良(BPD)是一种主要的早产儿慢性肺部疾病,也是早产儿长期呼吸系统疾病的重要原因。随着极早产儿存活率的提高,BPD的临床负担仍然很大。氧化还原失调,以氧化剂暴露、抗氧化能力和适应性信号反应之间的不平衡为特征,是BPD的主要致病机制,有助于肺泡和血管发育受损、炎症放大和肺修复缺陷。最新进展:目前的新生儿管理策略,包括优化呼吸支持、谨慎的氧气靶向、营养支持、咖啡因治疗和选择性使用皮质类固醇,可能会减少氧化负荷或调节氧化还原敏感性损伤途径。与此同时,抗氧化剂相关的干预措施——包括维生素、微量元素、谷胱甘肽相关疗法、天然产物和药理学试剂——已经证明了生物学上的合理性。关键问题:目前的干预措施并不能始终如一地纠正未成熟肺潜在的氧化还原失衡。抗氧化剂相关疗法的临床转化仍然有限,并且高度依赖于证据水平、干预时间和生物学背景。本文综述了氧化还原失调在BPD发病机制中的作用,并对氧化还原相关干预措施的临床和临床前证据进行了批判性的研究。未来方向:新兴的优先事项包括生物标志物引导的治疗、组学信息的风险分层、靶向肺输送、精确营养策略和综合多模式方法。BPD预防和治疗的未来进展可能取决于将氧化还原知情方法与已建立的新生儿护理、有针对性的干预和严格的长期临床评估相结合。Antioxid。氧化还原信号:00000 - 00000。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Antioxidants & redox signaling
Antioxidants & redox signaling 生物-内分泌学与代谢
CiteScore
14.10
自引率
1.50%
发文量
170
审稿时长
3-6 weeks
期刊介绍: Antioxidants & Redox Signaling (ARS) is the leading peer-reviewed journal dedicated to understanding the vital impact of oxygen and oxidation-reduction (redox) processes on human health and disease. The Journal explores key issues in genetic, pharmaceutical, and nutritional redox-based therapeutics. Cutting-edge research focuses on structural biology, stem cells, regenerative medicine, epigenetics, imaging, clinical outcomes, and preventive and therapeutic nutrition, among other areas. ARS has expanded to create two unique foci within one journal: ARS Discoveries and ARS Therapeutics. ARS Discoveries (24 issues) publishes the highest-caliber breakthroughs in basic and applied research. ARS Therapeutics (12 issues) is the first publication of its kind that will help enhance the entire field of redox biology by showcasing the potential of redox sciences to change health outcomes. ARS coverage includes: -ROS/RNS as messengers -Gaseous signal transducers -Hypoxia and tissue oxygenation -microRNA -Prokaryotic systems -Lessons from plant biology
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书